Currently, there are 26.83M common shares owned by the public and among those 23.67M shares have been available to trade.
Insiders at the company have transacted a total of 0 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 0 of these insider trades were purchases, accounting for 0 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The company’s stock has a 5-day price change of -50.90% and -67.32% over the past three months. SYRS shares are trading -64.32% year to date (YTD), with the 12-month market performance down to -98.86% lower. It has a 12-month low price of $0.14 and touched a high of $7.90 over the same period. SYRS has an average intraday trading volume of 2.03 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -50.78%, -57.94%, and -96.63% respectively.
Institutional ownership of Syros Pharmaceuticals Inc (NASDAQ: SYRS) shares accounts for 8.27% of the company’s 26.83M shares outstanding.
It has a market capitalization of $2.20M and a beta (3y monthly) value of 1.31. The earnings-per-share (ttm) stands at -$3.03. Price movements for the stock have been influenced by the stock’s volatility, which stands at 14.49% over the week and 10.01% over the month.
Earnings per share for the fiscal year are expected to increase by 74.11%, and 36.71% over the next financial year. EPS should grow at an annualized rate of 52.99% over the next five years, compared to 21.16% over the past 5-year period.
Looking at the support for the SYRS, a number of firms have released research notes about the stock. H.C. Wainwright stated their Buy rating for the stock in a research note on November 04, 2020, with the firm’s price target at $11-$15. Alliance Global Partners coverage for the Syros Pharmaceuticals Inc (SYRS) stock in a research note released on September 22, 2020 offered a Buy rating with a price target of $18. Wedbush was of a view on January 17, 2020 that the stock is Neutral, while JMP Securities gave the stock Mkt Outperform rating on March 08, 2019, issuing a price target of $18. Oppenheimer on their part issued Outperform rating on February 14, 2019.
